Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Study to Determine the Frequency and Associated Predictors of Hypoglycaemia in People With Type 2 Diabetes Mellitus Managed in Primary Care
Despite type 2 diabetes comprising the majority of cases of diabetes, the overall frequency
of hypoglycaemia in this group has not been as carefully documented as in type 1 diabetes,
particularly in relation to the clinical use of individual therapies in primary care.
The aim of this study is to provide robust data on the frequency and severity of
hypoglycaemia in people with type 2 diabetes managed in primary care, and assess and explore
associated risk factors.
Background - previous studies have provided robust evidence on the link between intensive
therapy and increased frequency of hypoglycaemia in people with type 1 diabetes. Despite type
2 diabetes comprising the majority of cases of diabetes, the overall frequency of
hypoglycaemia in this group has not been as carefully documented as in type 1 diabetes,
particularly in relation to the clinical use of individual therapies in primary care.
Recent prospective studies suggest that hypoglycaemia occurs more frequently than was
previously thought for people with type 2 diabetes, particularly those treated with insulin
and sulphonylureas. An increasingly elderly population, and earlier initiation of insulin and
other newer therapies and treatment combinations, may influence the risk and severity of
hypoglycaemic episodes.
The overall aim is to undertake research that provides robust data on the frequency and
severity of hypoglycaemia in people with type 2 diabetes managed in primary care, and assess
and explore associated risk factors.
PROSPECTIVE STUDY Aims - to prospectively evaluate the self-reported frequency and severity
of hypoglycaemia in people with type 2 diabetes managed in primary care (stratified by
participant treatment regime); to investigate the associated clinical and demographic
predictors of hypoglycaemia.
Methods - we will undertake a prospective, observational cohort study. Firstly, general
practices will be approached to participate in the study, with an aim of recruiting around 20
practices throughout the UK. All recruited sites will receive relevant study training for the
purposes of recruiting participants and collecting/recording research data. Participating
general practices will then identify potentially eligible individuals on their practice
register; individuals will be invited via a study invitation pack sent in the post or given
in person when they attend the practice. Individuals expressing an interest will be invited
to attend an appointment at their general practice where informed consent will be obtained
and baseline data collected (demographic, bio-medical and self-completion questionnaires).
Participants will be provided with relevant study materials (glucose monitoring diaries,
hypoglycaemia recording forms, and a blood glucose meter and strips) and asked to measure
their blood glucose and record any episodes of hypoglycaemia, over a period of 12-months.
Repeat biomedical and self-completion questionnaire data will be collected at 12-months
follow-up.
The overall sample size for the prospective study is 422, based on recruiting a quota of
participants on the following treatment regimens: 1) metformin only (n=62); 2) sulphonylurea
based (n=140); 3) insulin based (n=140); and 4) incretin based (Dipeptidyl peptidase-4 (DPP4)
or Glucagon-like peptide-1 (GLP-1)), (n=80). Practices will be asked to continue recruitment
until targets are met for each of the treatment groups.
CROSS SECTIONAL STUDY Aim - to provide data on the prevalence of hypoglycaemia in people with
type 2 diabetes who are managed in primary care and explore associated risk factors.
Methods - approach for participation will be made when potential volunteers attend for a
planned appointment for diabetes care (e.g. diabetes annual review, diabetic retinopathy
screening), through poster advertisement at the site. Their healthcare professional will also
explain that there is a researcher at the clinic who is recruiting individuals with type 2
diabetes to take part in a research study. The researcher will then approach potential
volunteers to provide a brief verbal explanation of the study, followed by a written
participant information sheet for them to read. Subsequently, for individuals who volunteer
to participate, they will be asked to sign a consent form and then given a questionnaire to
self-complete (at their appointment or take home and post back to the research team). In
addition, a researcher will obtain biomedical data from participants' medical records; no
data will be collected until at least 48 hours has passed from the time informed consent was
obtained, to allow time for participants who may change their mind about taking part.
The anticipated recruitment target for the cross-sectional study is to recruit up to 2000
participants.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |